XORTX Therapeutics Inc.
XORTX Therapeutics Inc.
Your view on XRTX.V
Overview
What the company does, where it operates, and who runs it.
About XORTX Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Allen Warren Davidoff
- Headquarters
- CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Allen Warren Davidoff
- Headquarters
- CA
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection.
It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy.
The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for XORTX Therapeutics Inc., and the rating behind it. XRTX.V last traded at C$0.81; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for XORTX Therapeutics Inc.. Starting points for XORTX Therapeutics Inc.: EPS -C$2.28, beta -0.10 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for XORTX Therapeutics Inc.. XORTX Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for XORTX Therapeutics Inc.. Trailing twelve-month EPS for XORTX Therapeutics Inc. stands at -C$2.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for XORTX Therapeutics Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
XORTX Therapeutics Inc. valued side by side against its closest peers. XORTX Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold XORTX Therapeutics Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by XORTX Therapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming XORTX Therapeutics Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming XORTX Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for XORTX Therapeutics Inc.. Coverage tracks XORTX Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.